Unknown

Dataset Information

0

Status of newborn screening and follow up investigations for Mucopolysaccharidoses I and II in Taiwan.


ABSTRACT: BACKGROUND:Mucopolysaccharidoses (MPS) are lysosomal storage diseases in which mutations of genes encoding for lysosomal enzymes cause defects in the degradation of glycosaminoglycans (GAGs). The accumulation of GAGs in lysosomes results in cellular dysfunction and clinical abnormalities. The early initiation of enzyme replacement therapy (ERT) can slow or prevent the development of severe clinical manifestations. MPS I and II newborn screening has been available in Taiwan since August 2015. Infants who failed the recheck at recall were referred to MacKay Memorial Hospital for a detailed confirmatory diagnosis. METHODS:From August 2015 to November 2017, 294,196 and 153,032 infants were screened using tandem mass spectrometry for MPS I and MPS II, respectively. Of these infants, 84 suspected cases (eight for MPS I; 76 for MPS II) were referred for confirmation. Urinary first-line biochemistry examinations were performed first, including urinary GAG quantification, two-dimensional electrophoresis, and tandem mass spectrometry assay for predominant disaccharides derived from GAGs. If the results were positive, a confirmative diagnosis was made according to the results of leukocyte enzymatic assay and molecular DNA analysis. Leukocyte pellets were isolated from EDTA blood and used for fluorescent ?-iduronidase (IDUA) or iduronate-2-sulfatase (IDS) enzymatic assay. DNA sequencing analysis was also performed. RESULTS:Normal IDS and IDUA enzyme activities were found in most of the referred cases except for four who were strongly suspected of having MPS I and three who were strongly suspected of having MPS II. Of these infants, three with novel mutations of the IDS gene (c.817C?>?T, c.1025A?>?G, and c.311A?>?T) and four with two missense mutations of the IDUA gene (C.300-3C?>?G, c.1874A?>?C; c.1037 T?>?G, c.1091C?>?T) showed significant deficiencies in IDS and IDUA enzyme activities (

SUBMITTER: Chuang CK 

PROVIDER: S-EPMC5970538 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Status of newborn screening and follow up investigations for Mucopolysaccharidoses I and II in Taiwan.

Chuang Chih-Kuang CK   Lin Hsiang-Yu HY   Wang Tuan-Jen TJ   Huang You-Hsin YH   Chan Min-Ju MJ   Liao Hsuan-Chieh HC   Lo Yun-Ting YT   Wang Li-Yun LY   Tu Ru-Yi RY   Fang Yi-Ya YY   Chen Tzu-Lin TL   Ho Hui-Chen HC   Chiang Chuan-Chi CC   Lin Shuan-Pei SP  

Orphanet journal of rare diseases 20180525 1


<h4>Background</h4>Mucopolysaccharidoses (MPS) are lysosomal storage diseases in which mutations of genes encoding for lysosomal enzymes cause defects in the degradation of glycosaminoglycans (GAGs). The accumulation of GAGs in lysosomes results in cellular dysfunction and clinical abnormalities. The early initiation of enzyme replacement therapy (ERT) can slow or prevent the development of severe clinical manifestations. MPS I and II newborn screening has been available in Taiwan since August 2  ...[more]

Similar Datasets

| S-EPMC7483722 | biostudies-literature
| S-EPMC6796768 | biostudies-literature
| S-EPMC7277946 | biostudies-literature
| S-EPMC8395728 | biostudies-literature
| S-EPMC8167547 | biostudies-literature
| S-EPMC8465393 | biostudies-literature
| S-EPMC10784669 | biostudies-literature
2005-01-18 | GSE1907 | GEO
| S-EPMC8886223 | biostudies-literature
| S-EPMC5203965 | biostudies-literature